91374-20-8CCCN(CCC)CCc1cccc2c1CC(=O)N2.ClXDXHAEQXIBQUEZ-UHFFFAOYSA-NRopinirole hydrochloride is a member of indoles.
91374-20-8DTXSID50238533FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 49 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Ropinirole binds the dopamine receptors D<sub>3</sub> and D<sub>2</sub>. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%). Route of Elimination: Ropinirole is extensively metabolized by the liver to inactive metabolites, and less than 10% of the administered dose is excreted as unchanged drug in urine. Half Life: 6 hours
ROPINIROLE HYDROCHLORIDE
Dopamine Agonists [MoA]; Nonergot Dopamine Agonist [EPC]
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Drugs that bind to and activate dopamine receptors.
BeschreibungReQuip was launched in the UK as a monotherapy or in combination with low-dose levodopa for the treatment of early-stage idiopathic Parkinson's disease. An eight step (24% overall yield) synthesis from isochroman provides access to ropinirole. It is a non-ergot postsynaptic dopamine D2 agonist with activity in the extrapyramidal system. It has weak or no significant activity at α2-adrenergic, 5-HT2 receptors and is inactive at 5-HT1, benzodiazepine, GABA, α1 and β adrenoreceptors. Thus it has essentially no CNS side effects, fewer dyskinesias and on-off fluctuations. In animals, it was able to reverse all motor deficits induced by MPTP. Tolerance is not developed and ropinirole has similar postsynaptic potency to apomorphine but with significantly less stereotyped behavior.
CHEMBL1200411CHEBI:8889Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ropinirole hydrochloride
vLess-DILI-concern
4
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
VerwendenAn antiparkinsonian agent. A selective dopamine D2-receptor agonist